Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease

International Journal of Biological Sciences

Volumn 8, Issue 5, 2012, Pages 663-671

  Hu, Peng ^a   Xuan, Qiang ^a   Hu, Bo ^a   Lu, Ling ^a   Wang, Jing ^a   Qin, Yuan Han ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cardiovascular disease; Fibroblast growth factor 23; Hypovitaminosis D; Left ventricular hypertrophy; Phosphate

Indexed keywords

CALCIMIMETIC AGENT; CHELATING AGENT; CINACALCET; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; NAPHTHALENE DERIVATIVE; PARATHYROID HORMONE; PHOSPHATE; POLYAMINE; SEVELAMER; VITAMIN D;

ANIMAL; BIOSYNTHESIS; BLOOD; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIET; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY TRANSPLANTATION; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SECONDARY HYPERPARATHYROIDISM; SECRETION; VASCULAR ENDOTHELIUM; VITAMIN D DEFICIENCY;

ANIMALS; CALCIMIMETIC AGENTS; CARDIOVASCULAR DISEASES; CHELATING AGENTS; DIET; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHATES; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC; VASCULAR CALCIFICATION; VITAMIN D; VITAMIN D DEFICIENCY;

ANIMALIA;

EID: 84863773456     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.3886     Document Type: Review

References (108)

1. Beale MG, Chan JC, Oldham SB, et al. Vitamin D: the discovery of its metabolites and their therapeutic applications. Pediatrics. 1976; 57: 729-41.
2. Stamp TC. Vitamin D metabolism. Recent advances. Arch Dis Child. 1973; 48: 2-7.
3. Haussler MR, Haussler CA, Jurutka PW, et al. The vitamin D hor-mone and its nuclear receptor: molecular actions and disease states. J Endocrinol. 1997; 154: S57-73.
4. Breidenbach A, Schlumbohm C, Harmeyer J. Peculiarities of vita-min D and of the calcium and phosphate homeostatic system in horses. Vet Res. 1998; 29: 173-86.
5. Amizuka N, Kwan MY, Goltzman D, et al. Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related pep-tide receptor expression in bone and cartilage. J Clin Invest. 1999; 103: 373-81.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: S1-201.
7. Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 1128-35.
8. London GM, Guérin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007; 18: 613-20.
9. Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window. Pediatr Nephrol. 2010; 25: 2413-30.
10. Williams S, Malatesta K, Norris K. Vitamin D and chronic kidney disease. Ethn Dis. 2009; 19: S5-S8-S11
11. Hu P, Hu B, Wang J, et al. Modulation of vitamin D signaling is a potential therapeutic target to lower cardiovascular risk in chronic kidney disease. Med Sci Monit. 2011; 17: HY14-20.
12. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002; 106: 100-5.
13. Mitsnefes MM. Cardiovascular complications of pediatric chronic kidney disease. Pediatr Nephrol. 2008; 23: 27-39.
14. Rakhit DJ, Marwick TH, Armstrong KA, et al. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart. 2006; 92: 1402-8.
15. Kaisar MO, Isbel NM, Johnson DW. Recent clinical trials of phar-macologic cardiovascular interventions in patients with chronic kidney disease. Rev Recent Clin Trials. 2008; 3: 79-88.
16. Reddy Vanga S, Good M, Howard PA, et al. Role of vitamin D in cardiovascular health. Am J Cardiol. 2010; 106: 798-805.
17. Santoro D, Gitto L, Ferraro A, et al. Vitamin D status and mortality risk in patients with chronic kidney disease. Ren Fail. 2011; 33: 184-91.
18. Teng M, Wolf M, Ofsthun MN, et al. Activated Injectable Vitamin D and Hemodialysis Survival: A Historical Cohort Study. J Am Soc Nephrol. 2005; 16: 1115-25.
19. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72: 1004-13.
20. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardio-vascular disease. Am J Med Sci. 2009; 338: 40-4.
21. Teng M, Wolf M, Lowrie E, et al. Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol Therapy. N Engl J Med. 2003; 349: 446-56.
22. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemo-dialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70: 1858-65.
23. Tentori F, Albert JM, Young EW, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2009; 24: 963-72.
24. Rajasree S, Rajpal K, Kartha CC, et al. Serum 25-hydroxyvitamin D3 levels are elevated in South Indian patients with ischemic heart disease. Eur J Epidemiol. 2001; 17: 567-71.
25. Mathew S, Lund RJ, Chaudhary LR, et al. Vitamin D receptor acti-vators can protect against vascular calcification. J Am Soc Nephrol. 2008; 19: 1509-19.
26. Kunitomo M, Kinoshita K, Bandô Y. Experimental atherosclerosis in rats fed a vitamin D, cholesterol-rich diet. J Pharmacobiodyn. 1981; 4: 718-23.
27. Reis JP, Michos ED, von Mühlen D, et al. Differences in vitamin D status as a possible contributor to the racial disparity in peripheral arterial disease. Am J Clin Nutr. 2008; 88: 1469-77.
28. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventro-lateral thalamic nucleus of the brain. Biochem Biophy Res Comm. 2000; 277: 494-8.
29. Nitta K. Relationship between Fibroblast Growth Factor-23 and Mineral Metabolism in Chronic Kidney Disease. Int J Nephrol 2010; 2010: 167984.
30. Brownstein CA, Zhang J, Stillman A, et al. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology. 2010; 151: 492-501.
31. Hughes SE. Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem. 1997; 45: 1005-19.
32. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006; 281: 6120-3.
33. Liu S, Vierthaler L, Tang W, et al. FGFR3 and FGFR4 Do not Medi-ate Renal Effects of FGF23. J Am Soc Nephrol. 2008; 19: 2342-50.
34. Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010; 77: 232-8.
35. Shaikh A, Berndt T, Kumar R. Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol. 2008; 23: 1203-10.
36. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem. 2003; 278: 2206-11.
37. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) deline-ate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004; 145: 5269-79.
38. Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007; 18: 2116-24.
39. Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of an-ti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009; 24: 1879-88.
40. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26: 345-8.
41. Perwad F, Zhang MY, Tenenhouse HS, et al.. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expres-sion in vitro. Am J Physiol Renal Physiol. 2007; 293: F1577-83.
42. Jüppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res. 2010; 25: 2091-7.
43. Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol. 2010; 25: 603-8.
44. Levine BS, Kleeman CR, Felsenfeld AJ. The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport. Clin J Am Soc Nephrol. 2009; 4: 1866-77.
45. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79: 1370-8.
46. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Cir-culation. 2009; 119: 2545-52.
47. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010; 95: 578-85.
48. Bacchetta J, Dubourg L, Harambat J, et al. The influence of glomer-ular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 2010; 95: 1741-8.
49. Westerberg PA, Linde T, Wikström B, et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Trans-plant. 2007; 22: 3202-7.
50. Perwad F, Azam N, Zhang MY, et al. Dietary and serum phospho-rus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005; 146: 5358-64.
51. Ito M, Sakai Y, Furumoto M, et al. Vitamin D and phosphate regu-late fibroblast growth factor-23 in K-562 cells. Am J Physiol Endo-crinol Metab. 2005; 288: E1101-9.
52. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005; 280: 2543-9.
53. Stubbs JR, Egwuonwu S. Is fibroblast growth factor 23 a harbinger of mortality in CKD? Pediatr Nephrol. 2011; [Epub ahead of print].
54. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-92.
55. Oliveira RB, Moysés RM. FGF-23: state of the art. J Bras Nefrol. 2010; 32: 323-31.
56. Tamei N, Ogawa T, Ishida H, et al. Serum fibroblast growth fac-tor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis. J Atheroscler Thromb. 2011; 18: 217-23.
57. Razzaque MS, St-Arnaud R, Taguchi T, et al. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant. 2005; 20: 2032-5.
58. Wesseling-Perry K, Pereira RC, Wang H, et al. Relationship between plasma fibroblast growth factor-23 concentration and bone miner-alization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009; 94: 511-7.
59. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16: 2205-15.
60. Komaba H, Fukagawa M. FGF23: a key player in mineral and bone disorder in CKD. Nefrologia. 2009; 29: 392-6.
61. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18: 2600-8.
62. Ix JH, Shlipak MG, Wassel CL, et al. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010; 25: 993-7.
63. Hagström E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009; 119: 2765-71.
64. Coen G, Mantella D, Sardella D, et al. Asymmetric dimethylarg-inine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients. J Nephrol. 2009; 22: 616-22.
65. Song GJ, Fiaschi-Taesch N, Bisello A. Endogenous parathyroid hormone-related protein regulates the expression of PTH type 1 receptor and proliferation of vascular smooth muscle cells. Mol Endocrinol. 2009; 23: 1681-90.
66. Cha H, Jeong HJ, Jang SP, et al. Parathyroid hormone accelerates decompensation following left ventricular hypertrophy. Exp Mol Med. 2010; 42: 61-8.
67. Di Leo C, Gallieni M, Bestetti A, et al. Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years af-ter parathyroidectomy. Clin Nephrol. 2003; 59: 59-63.
68. Amann K, Ritz E, Wiest G, et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol. 1994; 4: 1814-9.
69. Nishizawa Y, Miki T, Okui Y, et al. Deranged metabolism of lipids in patients with chronic renal failure: possible role of secondary hyperparathyroidism. Jpn J Med. 1986; 25: 40-5.
70. Ogard CG, Engelmann MD, Kistorp C, et al. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflam-mation related to atherosclerosis in patients with primary hy-perparathyroidism. Clin Endocrinol (Oxf). 2005; 63: 493-8.
71. De Boer IH, Gorodetskaya I, Young B, et al.. The severity of sec-ondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovas-cular disease. J Am Soc Nephrol. 2002; 13: 2762-9.
72. Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010; 95: 2172-9.
73. Zisman AL, Wolf M. Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease. Curr Opin Nephrol Hypertens. 2010; 19: 335-42.
74. Zoccali C. FGF-23 in dialysis patients: ready for prime time? Nephrol Dial Transplant. 2009; 24: 1078-81.
75. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113: 561-8.
76. Krajisnik T, Björklund P, Marsell R, et al. Fibroblast growth fac-tor-23 regulates parathyroid hormone and 1alpha-hydroxylase ex-pression in cultured bovine parathyroid cells. J Endocrinol. 2007; 195: 125-31.
77. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007; 117: 4003-8.
78. Yamashita H, Yamashita T, Miyamoto M, et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol. 2004; 151: 55-60.
79. Wesseling-Perry K, Salusky I. Redefining the pathogenesis of CKD-MBD: the critical role of FGF-23. Bol Pediatr. 2010; 50: 11-6.
80. Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol. 2005; 16: 2565-75.
81. Razzaque MS. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol Dial Transplant. 2009; 24: 4-7.
82. Butler KG. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient. Nephrol Nurs J. 2002; 29: 189-92.
83. Paoletti E, Bellino D, Gallina AM, et al. Is left ventricular hypertro-phy a powerful predictor of progression to dialysis in chronic kid-ney disease? Nephrol Dial Transplant. 2011; 26: 670-7.
84. Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportuni-ties for intervention. Am J Kidney Dis. 1996; 27: 347-54.
85. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001; 12: 1079-84.
86. Cerasola G, Nardi E, Palermo A, et al. Epidemiology and patho-physiology of left ventricular abnormalities in chronic kidney dis-ease: a review. J Nephrol. 2011; 24: 1-10.
87. Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol. 2010; 23: 619-25.
88. Negishi K, Kobayashi M, Ochiai I, et al. Association between fibro-blast growth factor 23 and left ventricular hypertrophy in mainte-nance hemodialysis patients. Comparison with B-type natriuretic peptide and cardiac troponin T. Circ J. 2010; 74: 2734-40.
89. Liu P, Bai X, Wang H, et al. Hypophosphatemia-mediated hypo-tension in transgenic mice overexpressing human FGF-23. Am J Physiol Heart Circ Physiol. 2009; 297: H1514-20.
90. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121: 4393-408.
91. Peiskerová M, Kalousová M, Kratochvílová M, et al. Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease? Kidney Blood Press Res. 2009; 32: 276-83.
92. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol. 2005; 16: S83-8.
93. Stenvinkel P. Endothelial dysfunction and inflammation-is there a link? Nephrol Dial Transplant. 2001; 16: 1968-71.
94. Kojima F, Uchida K, Ogawa T, et al. Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol. 2008; 40: 1067-74.
95. Manghat P, Fraser WD, Wierzbicki AS, et al. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010; 21: 1853-61.
96. Mirza MA, Larsson A, Lind L, et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009; 205: 385-90.
97. Balci M, Kirkpantur A, Gulbay M, et al. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int. 2010; 14: 425-32.
98. Hu MC, Shi M, Zhang J, et al. Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease. J Am Soc Nephrol. 2011; 22: 124-36.
99. Donate-Correa J, Mora-Fernández C, Martínez-Sanz R, et al. Ex-pression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol 2011; [Epub ahead of print].
100. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 rela-tionship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005; 90: 1519-24.
101. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006; 91: 3144-9.
102. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010; 5: 286-91.
103. Gonzalez-Parra M, Gonzalez-Casaus ML, Galán A, et al. Lantha-num carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant. 2011; 26: 2567-71.
104. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009; 20: 388-96.
105. Wetmore JB, Liu S, Krebill R, et al. Effects of cinacalcet and concur-rent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol. 2010; 5: 110-6.
106. Goetz R, Nakada Y, Hu MC, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA. 2010; 107: 407-12.
107. Economidou D, Dovas S, Papagianni A, et al. FGF-23 Levels before and after Renal Transplantation. J Transplant. 2009; 2009: 379082.
108. Evenepoel P, Meijers BK, de Jonge H, et al. Recovery of hyper-phosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008; 3: 1829-36.